A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Abstract Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX models were established following heterotop...

Full description

Bibliographic Details
Main Authors: Maria Eugénia Marques Da Costa, Sakina Zaidi, Jean-Yves Scoazec, Robin Droit, Wan Ching Lim, Antonin Marchais, Jerome Salmon, Sarah Cherkaoui, Raphael J. Morscher, Anouchka Laurent, Sébastien Malinge, Thomas Mercher, Séverine Tabone-Eglinger, Isabelle Goddard, Francoise Pflumio, Julien Calvo, Francoise Redini, Natacha Entz-Werlé, Aroa Soriano, Alberto Villanueva, Stefano Cairo, Pascal Chastagner, Massimo Moro, Cormac Owens, Michela Casanova, Raquel Hladun-Alvaro, Pablo Berlanga, Estelle Daudigeos-Dubus, Philippe Dessen, Laurence Zitvogel, Ludovic Lacroix, Gaelle Pierron, Olivier Delattre, Gudrun Schleiermacher, Didier Surdez, Birgit Geoerger
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-023-05320-0

Internet

https://doi.org/10.1038/s42003-023-05320-0

Similar Items